{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T13:28:35Z","timestamp":1756992515135},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00393-019-00709-x","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T13:11:19Z","timestamp":1570021879000},"page":"23-32","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapie der Psoriasisarthritis","Treatment of psoriatic arthritis"],"prefix":"10.1007","volume":"79","author":[{"given":"M.","family":"K\u00f6hm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"issue":"5","key":"709_CR1","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1111\/j.1365-2133.2008.09023.x","volume":"160","author":"K Reich","year":"2009","unstructured":"Reich\u00a0K, Kruger\u00a0K, Mossner\u00a0R, Augustin\u00a0M (2009) Epidemiology and clinical pattern of psoriatic arthritis in Germany: a\u00a0prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 160(5):1040\u20131047","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"709_CR2","first-page":"ii3","volume":"64","author":"PS Helliwell","year":"2005","unstructured":"Helliwell\u00a0PS, Taylor\u00a0WJ (2005) Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 64(Suppl 2):ii3\u20138","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"709_CR3","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/acr.20155","volume":"62","author":"LC Coates","year":"2010","unstructured":"Coates\u00a0LC, Helliwell\u00a0PS (2010) Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 62(7):965\u2013969","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10012","key":"709_CR4","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","volume":"386","author":"LC Coates","year":"2015","unstructured":"Coates\u00a0LC, Moverley\u00a0AR, McParland\u00a0L, Brown\u00a0S, Navarro-Coy\u00a0N, O\u2019Dwyer\u00a0JL et al (2015) Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a\u00a0UK multicentre, open-label, randomised controlled trial. Lancet 386(10012):2489\u20132498","journal-title":"Lancet"},{"key":"709_CR5","volume-title":"AWMF Therapieleitlinie der Psoriasis vulgaris","author":"AWMF","year":"2011","unstructured":"AWMF (2011) AWMF Therapieleitlinie der Psoriasis vulgaris. AWMF.org. Zugegriffen: 2011"},{"issue":"5","key":"709_CR6","first-page":"645","volume":"16","author":"A Nast","year":"2018","unstructured":"Nast\u00a0A, Amelunxen\u00a0L, Augustin\u00a0M, Boehncke\u00a0WH, Dressler\u00a0C, Gaskins\u00a0M et\u00a0al (2018) S3 Guideline for the treatment of psoriasis vulgaris, update\u2014Short version part 1\u2014Systemic treatment. J\u00a0Dtsch Dermatol Ges 16(5):645\u2013669","journal-title":"J Dtsch Dermatol Ges"},{"issue":"3","key":"709_CR7","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec\u00a0L, Smolen\u00a0JS, Ramiro\u00a0S, de Wit\u00a0M, Cutolo\u00a0M, Dougados\u00a0M et\u00a0al (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75(3):499\u2013510","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"709_CR8","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/bjd.14667","volume":"174","author":"LC Coates","year":"2016","unstructured":"Coates\u00a0LC, Murphy\u00a0R, Helliwell\u00a0PS (2016) New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation. Br J Dermatol 174(6):1174\u20131178","journal-title":"Br J Dermatol"},{"issue":"2","key":"709_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00105-016-3925-9","volume":"68","author":"F Behrens","year":"2017","unstructured":"Behrens\u00a0F, Thaci\u00a0D, Wollenhaupt\u00a0J, Kruger\u00a0K (2017) Psoriatic arthritis : Overview of drug therapy options and administration characteristics. Hautarzt 68(2):153\u2013169","journal-title":"Hautarzt"},{"issue":"7","key":"709_CR10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/rheumatology\/keq102","volume":"49","author":"L Eder","year":"2010","unstructured":"Eder\u00a0L, Chandran\u00a0V, Ueng\u00a0J, Bhella\u00a0S, Lee\u00a0KA, Rahman\u00a0P et al (2010) Predictors of response to intra-articular steroid injection in psoriatic arthritis. Rheumatology (Oxford) 49(7):1367\u20131373","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"709_CR11","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","volume":"51","author":"GH Kingsley","year":"2012","unstructured":"Kingsley\u00a0GH, Kowalczyk\u00a0A, Taylor\u00a0H, Ibrahim\u00a0F, Packham\u00a0JC, McHugh\u00a0NJ et al (2012) A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxf) 51(8):1368\u20131377","journal-title":"Rheumatology (Oxf)"},{"issue":"4","key":"709_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/ard.2011.152223","volume":"71","author":"A Baranauskaite","year":"2012","unstructured":"Baranauskaite\u00a0A, Raffayova\u00a0H, Kungurov\u00a0NV, Kubanova\u00a0A, Venalis\u00a0A, Helmle\u00a0L et al (2012) Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 71(4):541\u2013548","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"709_CR13","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3899\/jrheum.141596","volume":"43","author":"F Behrens","year":"2016","unstructured":"Behrens\u00a0F, Koehm\u00a0M, Arndt\u00a0U, Wittig\u00a0BM, Greger\u00a0G, Thaci\u00a0D et\u00a0al (2016) Does concomitant Methotrexate with Adalimumab influence treatment outcomes in patients with Psoriatic arthritis? Data from a\u00a0large observational study. J\u00a0Rheumatol 43(3):632\u2013639","journal-title":"J Rheumatol"},{"issue":"7","key":"709_CR14","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease\u00a0PJ, Gladman\u00a0DD, Collier\u00a0DH, Ritchlin\u00a0CT, Helliwell\u00a0PS, Liu\u00a0L et\u00a0al (2019) Etanercept and Methotrexate as Monotherapy or in combination for Psoriatic arthritis: primary results from a\u00a0randomized, controlled phase 3 trial. Arthritis Rheumatol 71(7):1112\u20131124. https:\/\/doi.org\/10.1002\/art.40851","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"709_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","volume":"73","author":"KM Fagerli","year":"2014","unstructured":"Fagerli\u00a0KM, Lie\u00a0E, van der Heijde\u00a0D, Heiberg\u00a0MS, Lexberg\u00a0AS, Rodevand\u00a0E et al (2014) The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 73(1):132\u2013137","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"709_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/BOR.0b013e328344fddb","volume":"23","author":"F Behrens","year":"2011","unstructured":"Behrens\u00a0F, Koehm\u00a0M, Burkhardt\u00a0H (2011) Update 2011: leflunomide in rheumatoid arthritis\u2014strengths and weaknesses. Curr Opin Rheumatol 23(3):282\u2013287","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"709_CR17","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1002\/art.20253","volume":"50","author":"JP Kaltwasser","year":"2004","unstructured":"Kaltwasser\u00a0JP, Nash\u00a0P, Gladman\u00a0D, Rosen\u00a0CF, Behrens\u00a0F, Jones\u00a0P et al (2004) Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a\u00a0multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50(6):1939\u20131950","journal-title":"Arthritis Rheum."},{"issue":"3","key":"709_CR18","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000091251","volume":"212","author":"P Nash","year":"2006","unstructured":"Nash\u00a0P, Thaci\u00a0D, Behrens\u00a0F, Falk\u00a0F, Kaltwasser\u00a0JP (2006) Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 212(3):238\u2013249","journal-title":"Dermatology"},{"issue":"2","key":"709_CR19","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1046\/j.1365-2133.1999.02977.x","volume":"141","author":"VC Ho","year":"1999","unstructured":"Ho\u00a0VC, Griffiths\u00a0CE, Albrecht\u00a0G, Vanaclocha\u00a0F, Leon-Dorantes\u00a0G, Atakan\u00a0N et al (1999) Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a\u00a01-year multicentre, randomized study. The PISCES Study Group. Br J Dermatol 141(2):283\u2013291","journal-title":"Br J Dermatol"},{"issue":"11","key":"709_CR20","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3899\/jrheum.140876","volume":"41","author":"ML Acosta Felquer","year":"2014","unstructured":"Acosta Felquer\u00a0ML, Coates\u00a0LC, Soriano\u00a0ER, Ranza\u00a0R, Espinoza\u00a0LR, Helliwell\u00a0PS et\u00a0al (2014) Drug therapies for peripheral joint disease in psoriatic arthritis: a\u00a0systematic review. J\u00a0Rheumatol 41(11):2277\u20132285","journal-title":"J Rheumatol"},{"issue":"12","key":"709_CR21","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/art.1780391210","volume":"39","author":"DO Clegg","year":"1996","unstructured":"Clegg\u00a0DO, Reda\u00a0DJ, Mejias\u00a0E, Cannon\u00a0GW, Weisman\u00a0MH, Taylor\u00a0T et\u00a0al (1996) Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study. Arthritis Rheum 39(12):2013\u20132020","journal-title":"Arthritis Rheum."},{"issue":"9","key":"709_CR22","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.3899\/jrheum.151376","volume":"43","author":"M Cutolo","year":"2016","unstructured":"Cutolo\u00a0M, Myerson\u00a0GE, Fleischmann\u00a0RM, Liote\u00a0F, Diaz-Gonzalez\u00a0F, Van den Bosch\u00a0F et al (2016) A phase III, randomized, controlled trial of Apremilast in patients with Psoriatic arthritis: results of the PALACE 2 trial. J\u00a0Rheumatol 43(9):1724\u20131734","journal-title":"J Rheumatol"},{"issue":"16","key":"709_CR23","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman\u00a0D, Rigby\u00a0W, Azevedo\u00a0VF, Behrens\u00a0F, Blanco\u00a0R, Kaszuba\u00a0A et\u00a0al (2017) Tofacitinib for Psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N\u00a0Engl J Med 377(16):1525\u20131536","journal-title":"N Engl J Med"},{"issue":"10","key":"709_CR24","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo\u00a0DH, Hrycaj\u00a0P, Miranda\u00a0P, Ramiterre\u00a0E, Piotrowski\u00a0M, Shevchuk\u00a0S et al (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 72(10):1613\u20131620","journal-title":"Ann. Rheum. Dis."},{"key":"709_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15023","author":"J Zweegers","year":"2017","unstructured":"Zweegers\u00a0J, Groenewoud\u00a0JM, van den Reek\u00a0JM, Otero\u00a0ME, van de Kerkhof\u00a0PC, Driessen\u00a0RJ et al (2017) Comparison of the one and 5\u2011years effectiveness of adalimumab, etanercept and ustekinumab in psoriasis patients in daily clinical practice: results from the prospective bioCAPTURE registry. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.15023","journal-title":"Br J Dermatol"},{"issue":"9625","key":"709_CR26","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi\u00a0CL, Kimball\u00a0AB, Papp\u00a0KA, Yeilding\u00a0N, Guzzo\u00a0C, Wang\u00a0Y et al (2008) Efficacy and safety of ustekinumab, a\u00a0human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a\u00a0randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371(9625):1665\u20131674","journal-title":"Lancet"},{"issue":"9625","key":"709_CR27","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp\u00a0KA, Langley\u00a0RG, Lebwohl\u00a0M, Krueger\u00a0GG, Szapary\u00a0P, Yeilding\u00a0N et al (2008) Efficacy and safety of ustekinumab, a\u00a0human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a\u00a0randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371(9625):1675\u20131684","journal-title":"Lancet"},{"issue":"9894","key":"709_CR28","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes\u00a0IB, Kavanaugh\u00a0A, Gottlieb\u00a0AB, Puig\u00a0L, Rahman\u00a0P, Ritchlin\u00a0C et al (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382(9894):780\u2013789","journal-title":"Lancet"},{"issue":"6","key":"709_CR29","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin\u00a0C, Rahman\u00a0P, Kavanaugh\u00a0A, McInnes\u00a0IB, Puig\u00a0L, Li\u00a0S et al (2014) Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6\u2011month and 1\u2011year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73(6):990\u2013999","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"709_CR30","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","volume":"48","author":"EG Araujo","year":"2019","unstructured":"Araujo\u00a0EG, Englbrecht\u00a0M, Hoepken\u00a0S, Finzel\u00a0S, Kampylafka\u00a0E, Kleyer\u00a0A et\u00a0al (2019) Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. Semin Arthritis Rheum 48(4):632\u2013637","journal-title":"Semin Arthritis Rheum"},{"issue":"14","key":"709_CR31","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease\u00a0PJ, McInnes\u00a0IB, Kirkham\u00a0B, Kavanaugh\u00a0A, Rahman\u00a0P, van der Heijde\u00a0D et al (2015) Secukinumab inhibition of Interleukin-17A in patients with Psoriatic arthritis. N Engl J Med 373(14):1329\u20131339","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"709_CR32","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley\u00a0RG, Elewski\u00a0BE, Lebwohl\u00a0M, Reich\u00a0K, Griffiths\u00a0CE, Papp\u00a0K et\u00a0al (2014) Secukinumab in plaque psoriasis\u2014results of two phase 3 trials. N\u00a0Engl J Med 371(4):326\u2013338","journal-title":"N Engl J Med"},{"issue":"1","key":"709_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","volume":"130","author":"JG Krueger","year":"2012","unstructured":"Krueger\u00a0JG, Fretzin\u00a0S, Suarez-Farinas\u00a0M, Haslett\u00a0PA, Phipps\u00a0KM, Cameron\u00a0GS et al (2012) IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J\u00a0Allergy Clin Immunol 130(1):145\u2013154","journal-title":"J Allergy Clin Immunol"},{"issue":"9993","key":"709_CR34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CE Griffiths","year":"2015","unstructured":"Griffiths\u00a0CE, Reich\u00a0K, Lebwohl\u00a0M, van de Kerkhof\u00a0P, Paul\u00a0C, Menter\u00a0A et al (2015) Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER\u20112 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 386(9993):541\u2013551","journal-title":"Lancet"},{"issue":"2","key":"709_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/BOR.0000000000000147","volume":"27","author":"PJ Mease","year":"2015","unstructured":"Mease\u00a0PJ (2015) Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 27(2):127\u2013133","journal-title":"Curr Opin Rheumatol"},{"issue":"24","key":"709_CR36","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","volume":"370","author":"PJ Mease","year":"2014","unstructured":"Mease\u00a0PJ, Genovese\u00a0MC, Greenwald\u00a0MW, Ritchlin\u00a0CT, Beaulieu\u00a0AD, Deodhar\u00a0A et al (2014) Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N\u00a0Engl J Med 370(24):2295\u20132306","journal-title":"N Engl J Med"},{"issue":"6","key":"709_CR37","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.jaad.2014.08.039","volume":"71","author":"K Papp","year":"2014","unstructured":"Papp\u00a0K, Leonardi\u00a0C, Menter\u00a0A, Thompson\u00a0EH, Milmont\u00a0CE, Kricorian\u00a0G et\u00a0al (2014) Safety and efficacy of brodalumab for psoriasis after 120\u00a0weeks of treatment. J\u00a0Am Acad Dermatol 71(6):1183\u20131190.e3","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"709_CR38","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jaad.2014.10.026","volume":"72","author":"K Papp","year":"2015","unstructured":"Papp\u00a0K, Menter\u00a0A, Strober\u00a0B, Kricorian\u00a0G, Thompson\u00a0EH, Milmont\u00a0CE et al (2015) Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology 72(3):436\u2013439 (e1)","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"709_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt\u00a0A, Papp\u00a0KA, Griffiths\u00a0CE, Randazzo\u00a0B, Wasfi\u00a0Y, Shen\u00a0YK et al (2017) Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J\u00a0Am Acad Dermatol 76(3):405\u2013417","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"709_CR40","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates\u00a0LC, Kavanaugh\u00a0A, Mease\u00a0PJ, Soriano\u00a0ER, Acosta-Felquer\u00a0LM, Armstrong\u00a0AW et al (2016) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 68(5):1060\u20131071","journal-title":"Arthritis Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-00709-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-019-00709-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-00709-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T05:20:19Z","timestamp":1695273619000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-019-00709-x"}},"subtitle":["Gibt es eine Differenzialindikation?","Are there differential indications?"],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["709"],"URL":"https:\/\/doi.org\/10.1007\/s00393-019-00709-x","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,1]]},"assertion":[{"value":"1 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die Autoren geben folgende Interessenkonflikte an: M.\u00a0K\u00f6hm: Forschungsunterst\u00fctzung von Janssen, Pfizer, AbbVie; Vortrags\u2011\/Beraterhonorar: Janssen, Pfizer, Celgene. F.\u00a0Behrens: Forschungsunterst\u00fctzung: AbbVie, Pfizer, Roche, Chugai, Novartis; Vortrags\u2011\/Beraterhonorar: AbbVie, Pfizer, Roche, Chugai, UCB, BMS, Celgene, MSD, Novartis, Biotest, Janssen, Genzyme, Lilly, Sandoz.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}